NEW YORK, Oct. 31, 2013 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"), a leader in the emerging cellular therapy industry, announced today that the Company and its subsidiary, Progenitor Cell Therapy ("PCT"), will present at multiple upcoming conferences in November.
BIO-Europe 2013-19th Annual International Partnering Conference
- Date and Time: Monday, November 4, 2013, 2:45 PM CEST
- Venue: Messe Wien Exhibition and Congress Center, Vienna, Austria
- Session: "What is the role of large pharma in developing advanced therapy medicinal products—are they essential or not?"
- Moderator: Robert A. Preti, Ph.D., Chief Scientific Officer, NeoStem, and President, PCT
Landmark Venture Forum – Investing for Cures 2013
- Date and Time: Wednesday, November 6, 2013, 2:00 PM EST
- Venue: Union League Club, New York, New York
- Session: Company Presentation
- Speaker: Robin L. Smith, MD, MBA, Chairman and CEO, NeoStem
American Heart Association Annual Scientific Sessions 2013
- Venue: Dallas Convention Center, Dallas, Texas
- Date and Time: Monday, November 18, 2013, 9:00 AM CST
- Session 1: "Clinical Science Special Reports"
- Panelist: Douglas W. Losordo, MD, Chief Medical Officer, NeoStem
- Date and Time: Tuesday, November 19, 2013, 9:00 AM CST
- Session 2: "George E. Brown Memorial Lecture and Adult Stem Cells: Cardiac Homeostasis and Repair"
- Moderator: Douglas W. Losordo, MD, Chief Medical Officer, NeoStem
11th Annual Commercial Translation of Regenerative Medicine 2013
- Date and Time: Tuesday, November 26, 4:20 PM BST
- Venue: Charing Cross Hotel, London, United Kingdom
- Session: "Case Study - Capturing and Preparing for Licensing and Acquisition"
- Speaker: Robin L. Smith, MD, MBA, Chairman and CEO, NeoStem
London Regenerative Medicine Network
- Date and Time: Tuesday, November 26, 6:35 PM BST
- Venue: University College London, Bloomsbury campus, London, United Kingdom
- Session: Company Presentation
- Speaker: Robin L. Smith, MD, MBA, Chairman and CEO, NeoStem
About NeoStem, Inc.
NeoStem, Inc. is a leader in the emerging cellular therapy industry. Our business model includes the development of novel proprietary cell therapy products as well as operating a contract development and manufacturing organization providing services to others in the regenerative medicine industry. The combination of a therapeutic development business and revenue-generating service provider business provides the Company with capabilities for cost effective in-house product development and immediate revenue and cash flow generation.
For more information, please visit www.neostem.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy, including with respect to the Company's research and development and clinical evaluation efforts towards commercialization of cellular therapies, including with respect to AMR-001, the future of the regenerative medicine industry and the role of stem cells and cellular therapy in that industry and the Company's ability to successfully grow its contract development and manufacturing business. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 11, 2013 and in the Company's periodic filings with the SEC. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.